CRP and hematologic disorder: In conclusion, we currently observe the kinetic changes of IL‐6, PCT, and CRP to investigate their role in initial antibiotic efficacy evaluation of FN patients with hematological disorder, confirming IL‐6 and CRP as the biomarkers.